What is King Pharmaceuticals's debt-to-equity?

King Pharmaceuticals (KG) reported debt-to-equity of 1.5× in Q1 2026.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

King Pharmaceuticals KG Debt-to-equity

Debt-to-equity at other companies

Arch Capital GroupACGL

0.1×0.0×

Everest GroupEG

0×0.0×

SiriusPointSPNT

0.3×0.0×

Skyward Specialty Insurance Group, Inc.SKWD

0×0.0×

Selective Insurance GroupSIGI

0.3×0.0×

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Where this comes from

Calculated from King Pharmaceuticals’s reported figures.

total debt/total stockholders equity=1.5×

Based on the most recent quarter.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's debt-to-equity?: King Pharmaceuticals (KG) reported debt-to-equity of 1.5× in Q1 2026.
What does debt-to-equity mean?: Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.